Li Lin, Bading James, Yazaki Paul J, Ahuja Amitkumar H, Crow Desiree, Colcher David, Williams Lawrence E, Wong Jeffrey Y C, Raubitschek Andrew, Shively John E
Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.
Bioconjug Chem. 2008 Jan;19(1):89-96. doi: 10.1021/bc700161p. Epub 2007 Nov 8.
Radiolabeled anti-carcinoembryonic antigen (CEA) antibodies have the potential to give excellent images of a wide variety of human tumors, including tumors of the colon, breast, lung, and medullar thyroid. In order to realize the goals of routine and repetitive clinical imaging with anti-CEA antibodies, it is necessary that the antibodies have a high affinity for CEA, low cross reactivity and uptake in normal tissues, and low immunogenicity. The humanized anti-CEA antibody hT84.66-M5A (M5A) fulfills these criteria with an affinity constant of >10 (10) M (-1), no reactivity with CEA cross-reacting antigens found in normal tissues, and >90% human protein sequence. A further requirement for routine clinical use of radiolabeled antibodies is a versatile method of radiolabeling that allows the use of multiple radionuclides that differ in their radioemissions and half-lives. We describe a versatile bifunctional chelator, DO3A-VS (1,4,7-tris(carboxymethyl)-10-(vinylsulfone)-1,4,7,10-tetraazacyclododecane) that binds a range of radiometals including 111 In for gamma-ray imaging and 64Cu for positron emission tomography (PET), and which can be conjugated with negligible loss of immunoreactivity either to sulfhydryls (SH) in the hinge region of lightly reduced immunoglobulins or surface lysines (NH) of immunoglobulins. Based on our correlative studies comparing the kinetics of radiolabeled anti-CEA antibodies in murine models with those in man, we predict that 64Cu-labeled intact, humanized antibodies can be used to image CEA positive tumors in the clinic.
放射性标记的抗癌胚抗原(CEA)抗体有潜力为包括结肠癌、乳腺癌、肺癌和甲状腺髓样癌在内的多种人类肿瘤提供优质图像。为实现使用抗CEA抗体进行常规和重复临床成像的目标,抗体必须对CEA具有高亲和力、在正常组织中的交叉反应性和摄取率低,且免疫原性低。人源化抗CEA抗体hT84.66 - M5A(M5A)满足这些标准,其亲和常数>10(10)M(-1),与正常组织中发现的CEA交叉反应抗原无反应,且人类蛋白质序列>90%。放射性标记抗体常规临床应用的另一个要求是一种通用的放射性标记方法,该方法允许使用具有不同放射发射和半衰期的多种放射性核素。我们描述了一种通用的双功能螯合剂DO3A - VS(1,4,7 - 三(羧甲基)- 10 - (乙烯砜)- 1,4,7,10 - 四氮杂环十二烷),它能结合一系列放射性金属,包括用于γ射线成像的111In和用于正电子发射断层扫描(PET)的64Cu,并且可以与轻度还原的免疫球蛋白铰链区的巯基(SH)或免疫球蛋白的表面赖氨酸(NH)偶联,免疫反应性损失可忽略不计。基于我们在小鼠模型和人类中比较放射性标记抗CEA抗体动力学的相关研究,我们预测64Cu标记的完整人源化抗体可用于临床成像CEA阳性肿瘤。